Fig. 1From: No increased risk of glucose metabolism disorders in adults with growth hormone deficiency undergoing long-term treatment with biosimilar somatropin (Omnitrope®): data from an observational, longitudinal study– HbA1c (± SD) over 3.5 years in (a) treatment-naïve and pretreated adult GHD patients and (b) patients who developed new-onset diabetes mellitus (safety population)Back to article page